Sbir phase II, topic 429: a new paradigm for autologous and allogeneic cell therapy manufacturing
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00028
- Awardee
-
Proteios Technology, Inc. UEI G6QLLQD9UMT1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,049,979
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20231 · Posted Jul 20, 2022
- Contract value 100% obligated
- $2,049,979.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Issaquah, WA, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,049,979 |
About this award
The National Cancer Institute awarded a $2.05 million Small Business Innovation Research Phase II contract to Proteios Technology, Inc., a small disadvantaged business based in Issaquah, Washington. Under this firm fixed-price definitive contract, Proteios will conduct research and development activities through February 2026 to develop a new paradigm for autologous and allogeneic cell therapy manufacturing. The contract was awarded on September 15, 2023, following a pre-solicitation notice issued by the National Institutes of Health and Centers for Disease Control and Prevention in July 2022 that sought proposals across more than 150 research topics designed to stimulate technological innovation within small businesses.
This Phase II award builds on Proteios's expertise in sustainable protein purification and cell separation technologies for the biopharmaceutical and cell therapy sectors. The contract supports the company's continued innovation in manufacturing processes that aim to reduce costs and improve efficiency in cell therapy production. As a total small business set-aside contract under the SBIR program, this award reflects the National Cancer Institute's commitment to leveraging small business capabilities to advance cellular therapy solutions and strengthen their role in meeting critical federal research objectives.
Quick answers
Who was awarded contract 75N91023C00028?
75N91023C00028 was awarded to Proteios Technology, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023C00028 worth?
The government has obligated $2,049,979 on 75N91023C00028.
Was contract 75N91023C00028 competed?
The extent of competition for 75N91023C00028 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award